157 results about "Protein markers" patented technology

Provided in the present invention are a method for constructing a pre-eclampsia risk assessment prediction model, and a prediction product, a prediction system, and a related application of the method. Specifically, the method of the present invention comprises: constructing a logistic regression analysis model on the basis of acquired clinical indexes of a pregnant woman, and obtaining the prior probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman; performing median-of-multiples calibration on an acquired MAP, IGFBP1 and / or PLGF of the pregnant woman, and respectively constructing a multivariate normal distribution model for a sick pregnant woman and a multivariate normal distribution model for a healthy pregnant woman on the basis of an MAP MoM value and an IGFBP1 MoM value and / or a PLGF MoM value, so as to obtain the conditional probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman; and in view of the prior probability and the conditional probability, calculating the posterior probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman on the basis of a Bayesian model. In the present invention, the detection of related protein markers and the obtaining of maternal clinical information data are relatively easy, the accuracy of predicting early-onset pre-eclampsia and late-onset pre-eclampsia is relatively high, and clinical popularization and application are facilitated; therefore, the present invention is of great value to the prevention and early diagnosis of a disease.

The invention relates to autophagy extracellular vesicles capable of swallowing viruses as well as a preparation method and application of the autophagy extracellular vesicles, and relates to the technical field of biological medicines. The preparation method of the high-purity autophagy extracellular vesicles is provided for the first time, the purity of the high-purity autophagy extracellular vesicles exceeds 85%, and the high-purity autophagy extracellular vesicles are rich in various protein markers. CVB4 virus is used for infecting the autophagy extracellular vesicles, it is found that compared with common extracellular vesicles, the autophagy extracellular vesicles contain complete CVB4 virus particles, and the virus particles carried by the autophagy extracellular vesicles can more effectively infect brain and spleen tissue of a mouse, so that the autophagy extracellular vesicles can be used for treating the brain and spleen tissue of the mouse; therefore, the autophagy extracellular vesicle disclosed by the invention can break through the limitation of a host virus specific receptor, efficiently infect corresponding tissues and enlarge the virus tissue tropism. Therefore, the autophagy extracellular vesicle disclosed by the invention can be used for screening antiviral drugs, and also has important significance for constructing a virus infected animal model.

Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker.　More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.

The invention discloses a gastric cancer biomarker composition as well as a screening method and application thereof, and belongs to the technical field of bioinformatics. The screening method of the gastric cancer biomarker composition comprises the following steps: firstly, collecting blood specimens of a gastric cancer patient and a healthy control, carrying out high-throughput plasma proteomics detection, and screening out differential expression proteins; and verifying the candidate protein markers by using a prospective queue in the British biological sample library, and finally determining 17 core proteins to obtain the gastric cancer biomarker composition. A gastric cancer risk prediction model is constructed by combining clinical risk factors and protein expression levels of gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the invention can realize accurate layering of gastric cancer risks, decision curve analysis shows that the net benefit of the model is obviously superior to that of a traditional screening method, and an efficient tool is provided for early warning and personalized intervention of gastric cancer.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention discloses a probe Cvs-B-NHS based on a coumarin derivative as well as a preparation method and application of the probe Cvs-B-NHS. According to the fluorescent probe Cvs-B-NHS of the coumarin derivative, a coumarin mother nucleus and succinimide ester are organically combined, the excellent fluorescence characteristic of coumarin is reserved, efficient protein labeling capacity is achieved, high-sensitivity fluorescence signal output and specific labeling of protein are achieved, and the fluorescent probe Cvs-B-NHS has the advantages of being high in sensitivity and high in sensitivity. And the accuracy and reliability of protein detection and imaging are improved. The invention discloses a TDP-43 protein phase separation labeling method based on a Cvs-B-NHS probe, which provides a new means for researching the action mechanism of a TDP-43 (G335D) mutant in neurodegenerative diseases, and is beneficial to promoting the research progress in the field of neurodegenerative diseases. The application of the Cvs-B-NHS probe in evaluating the polarity change of the microenvironment in the protein liquid-liquid phase separation process in the cytoplasm environment caused by mitochondrial signal disturbance provides a powerful tool for the research of the protein phase separation microenvironment.

The invention relates to an immune Raman multicolor imaging kit for liver cancer prediction and evaluation, the immune Raman multicolor imaging kit comprises five Raman probes, and the Raman probes are composed of Raman balls and antibodies connected to the surfaces of the Raman balls; wherein the Raman sphere is formed by polymerizing a triple bond monomer and (i) acrylic acid or (ii) styrene and acrylic acid, the particle size is 10-100 nm, and the Raman shift is 1800-2800 cm <-1 >; antibodies of the five Raman probes are respectively selected from one of an AFP antibody, an HBX antibody, a GPC3 antibody, a GS antibody and a CD34 antibody. The immune Raman multicolor imaging reagent and kit provided by the invention can realize one-step marking and multiple color development of five liver cancer related protein markers in the same liver tissue slice. Compared with a multiple fluorescence immunohistochemical technology, the method has remarkable advantages in efficiency and precision. Experiments show that the detection result is consistent with the clinical diagnosis result, and the application potential is huge.

The invention discloses an application of a biomarker in typing of polymorphic glioblastoma, and the biomarker is combined by selecting at least one of the following categories: at least one of a plurality of gene markers for identifying a proliferative type, a protein marker DLL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, a protein marker DL3 and / or Ki67, and a protein marker DL3 and / or Ki67. At least one of a plurality of gene markers for identifying the neurosynaptic type, a protein marker GRMM3 and / or FGFR2; at least one of a plurality of gene markers for identifying the metabolic type, a protein marker P16; and at least one of a plurality of gene markers for identifying the immune regulation type, and at least one of protein markers CD44, C1R and Ki67. The application provides comprehensive features of EAS-GBM, and enhances understanding of occurrence, clinical stratification and treatment strategies of different ancestral tumors.

The invention relates to a urine protein marker for depression and bipolar affective disorder and application of the urine protein marker in early diagnosis. Specifically, the invention relates to application of a reagent for detecting the content of protein in urine of a subject in preparation of a reagent for diagnosing depression and bipolar affective disorder, and the protein in the urine is selected from the following combinations: Uniprot ID: P11766, H7BY57, O95967, O95433, K7ELM9, P15328 and P68371.

Provided are a method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases, and a method for discriminating atopic dermatitis and other skin diseases using said protein marker.　More specifically, the method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases includes collecting, from a sample collected from the skin of a subject, at least one protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2, and PRG2.

The invention relates to the technical field of western blot analysis, and discloses a full-automatic micro western blot analyzer and an analysis method thereof. The full-automatic micro protein immunoblotting analyzer comprises a full-automatic control system, a horizontal control system, a protein separation system, a temperature control system, a liquid path control system, an ultraviolet curing module, an antibody incubation module and a chip scanning module, the horizontal control system controls the protein separation system to horizontally move and correct; the protein separation system carries out protein separation; the temperature control system is used for carrying out constant-temperature control and temperature adjustment; the liquid path control system is used for filling a constant-temperature reagent into the protein separation system and extracting waste liquid; the ultraviolet light curing module is used for carrying out in-situ immobilization on the separated protein; the antibody incubation module is used for performing antibody incubation on the fixed protein marker; and the chip scanning module is used for chip result reading and data processing. According to the invention, full-automatic control, accurate temperature control and automatic horizontal correction can be realized.

The invention belongs to the field of biological medicine, and particularly relates to a protein marker for lung metastasis of primary liver cancer and application of the protein marker. The invention discloses a protein marker for lung metastasis of primary liver cancer. The protein marker is selected from at least one of rs2 protein, rcsd1 protein, rbbp9 protein, prl6a1 protein, ubxn4 protein and mospd2 protein. According to the invention, mass spectrometry is carried out by using an HPLC-MS / MS mass spectrometry system and an unlabeled quantitative proteomics method; and then searching mass spectrum data by utilizing a non-limited amino acid protein modification analysis method, and verifying whether differential protein substances have significance or not according to P-value, so as to finally obtain six proteins with significant difference, namely, the rs2 protein, the rcsd1 protein, the rbbp9 protein, the prl6a1 protein, the ubxn4 protein and the mospd2 protein. The protein marker provided by the invention has higher sensitivity and specificity, and the combination of the six proteins has better detection efficacy.

The application discloses an electrochemical sensor for detecting IBD protein markers and a preparation method thereof. The electrochemical sensor is composed of a CNT-embedded semi-cured PDMS flexible substrate, deposited gold nanoparticles and a nucleic acid sensing layer. The nucleic acid sensing layer comprises a tumor necrosis factor-alpha sensor, an interleukin 6 sensor, an interleukin 8 sensor, a transforming growth factor beta 1 sensor, a reference electrode and a counter electrode. The tumor necrosis factor-alpha sensor, the interleukin 6 sensor, the interleukin 8 sensor and the transforming growth factor beta 1 sensor all adopt single-stranded aptamers modified by a signal molecule methylene blue, and the nucleotide sequences corresponding to the single-stranded aptamers are SEQ ID NO. 1-4. The application can improve the modulus matching of the sensor and human tissue and excellent biocompatibility, realize accurate detection of low-concentration biomarkers and stable signal output of the sensor under a strain working condition.

The invention belongs to the technical field of biology, and particularly relates to a method for rapidly and multiply detecting breast cancer related protein markers based on cas12a and application of the method. HER2, CEA, CA15-3 and CD63 are taken as protein markers, are fixed on magnetic beads through biotin and streptavidin and are used for recognizing and capturing proteins, meanwhile, protein detection is converted into deoxyribozyme recognition of a cyclic sequence, and signal amplification is performed through cas12a; the method provided by the invention can be used for detecting four breast cancer protein markers in a system in a short time, is simple to operate, does not need to heat up, has high accuracy and specificity, accelerates the progress of breast cancer diagnosis and postoperative and prognostic diagnosis, and provides reference for subsequent treatment of clinicians.

The application belongs to the technical field of biomedicine, and particularly relates to a construction system of a cerebral amyloid angiopathy recognition model, a storage medium and a kit. Based on plasma proteomic data of cerebral amyloid angiopathy patients and normal old controls, six key protein markers closely related to cerebral amyloid angiopathy are screened out. The application also provides a model for recognizing cerebral amyloid angiopathy based on a combination of six plasma protein biomarkers. The model shows excellent performance in multiple independent data sets, can accurately distinguish cerebral amyloid angiopathy patients from normal old controls, and further distinguish cerebral amyloid angiopathy patients with high-risk cerebral hemorrhage risk from those with low-risk cerebral hemorrhage risk. The application provides a new tool for early diagnosis and hemorrhage risk assessment of cerebral amyloid angiopathy.

The present invention provides methods and compositions based on a non-naturally occurring nucleic acid construct encoding a fusion protein for quantifying secretion levels in an individual cell, which may comprise a protein sequence comprising a cytoplasmic domain, a transmembrane domain, and a vesicular domain, wherein the vesicular domain may comprise a sequence of protein marks, wherein upon expression of the fusion protein by a cell, the fusion protein localizes to the membrane of a secretory vesicle such that the protein mark is located in the lumen of the secretory vesicle, and wherein the protein mark binds to a cell-impermeable marker;whereby, after the secretion of the contents of the secretory vesicle, the protein tag is exposed to the cell-impermeable marker, the fusion protein is recycled back into the cell, and the individual cell is tagged with the marker in relation to the amount of secretion.

The present invention provides a kit for early screening of hepatocellular carcinoma, comprising a gene marker detection reagent and a protein marker detection reagent. The invention also provides a preparation method and application of the kit. The kit comprising specific gene markers and protein markers of the present invention has been demonstrated to be effective in achieving early screening of HCC in community populations, particularly in prospective studies.

The present invention belongs to the field of bioproteomics technology, specifically relating to a hair identification method based on 4D Label-Free technology and the protein markers used to identify hair. This identification method utilizes 4D Label-Free analysis technology to obtain differentially expressed protein markers capable of distinguishing between human axillary and pubic hair samples. The protein GPRC5D described in the present invention is a protein marker specific for axillary hair, and CTNNBIP1 is a protein marker specific for pubic hair. The hair protein markers obtained in this invention can be used to identify case-related hair samples as pubic hair, which is of great significance for the determination of criminal cases.

The invention discloses a plasma protein marker for identifying or assisting in identifying parathyroid cancer and parathyroid adenoma and application of the plasma protein marker. The method comprises the following steps: firstly, collecting plasma specimens of a parathyroid carcinoma patient and a parathyroid adenoma patient before an operation, and screening through an unmarked quantitative proteomics technology to obtain 24 differential expression proteins; on the basis of the other part of plasma specimens of the parathyroid carcinoma patient and the parathyroid adenoma patient collected before the operation, the 24 differential expression proteins are verified through a parallel reaction monitoring technology; finally, three plasma protein markers (myoglobin, coronin-1A and a polyimmunoglobulin receptor) which can be used for identifying the parathyroid carcinoma and the parathyroid adenoma are obtained. Experiments prove that the plasma protein marker or the combination thereof can be used for auxiliary differential diagnosis of parathyroid carcinoma and parathyroid adenoma, and has important significance for improving the accuracy of preoperative diagnosis of parathyroid carcinoma.

The invention discloses a protein marker for diagnosing heavy metal related cognitive impairment of middle-aged and elderly people and application thereof, a kit and a risk assessment model, and belongs to the technical field of biomedicine, the protein marker comprises a combination of TSKU, SOD3, CES2, PSMB10 and C1QA, the expression level of TSKU and CES2 in heavy metal related cognitive impairment patients is reduced, and the expression level of CES2 in the heavy metal related cognitive impairment patients is reduced. The expression levels of SOD3, PSMB10 and C1QA in heavy metal middle-aged and elderly cognitive impairment patients are up-regulated, a clinical model is constructed by detecting the expression levels of TSKU, SOD3, CES2, PSMB10 and C1QA and combining clinical information, and early diagnosis of cognitive impairment symptoms of heavy metal related middle-aged and elderly people can be realized, so that the sensitivity and efficiency of detection are improved. The constructed model is verified, and intervention measures can be taken actively through the early detection method, so that the progress of cognitive disorder symptoms can be delayed, the disability and fatality rate can be reduced, and even early curing can be realized.

The invention provides a multi-omics integrated marker for early screening of colorectal cancer, which comprises an lncRNA marker combination, a protein marker combination, an mRNA marker combination, a metabolism marker combination and a methylation marker combination, and relates to the technical field of gene detection and medical treatment. According to the invention, 11 groups of colorectal cancer tissues and para-carcinoma tissues paired with the colorectal cancer tissues are subjected to transcriptome, proteome and metabolome sequencing, and 61 cases of colorectal cancer tissues and 24 cases of para-carcinoma tissues are subjected to simplified methylation sequencing; by integrating and analyzing the multi-omics data, a multi-level interaction network is obtained, and the network contains lncRNA, protein, mRNA, metabolites and DNA methylation markers which have a close interaction relationship, and has a wide application prospect in diagnosis and treatment of colorectal cancer.

Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and / or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.

The invention discloses an ultra-stable red fluorescent protein. The fluorescent protein disclosed by the invention is a protein with an amino acid sequence SEQ ID No.4. Experiments prove that the fluorescent protein has excellent electron microscope sample preparation resistance, can retain more fluorescent signals after osmic acid treatment, and can tolerate embedding of Epon resin; meanwhile, the fluorescent protein has excellent thermal stability, and can retain more fluorescent signals at 90 DEG C; in addition, the fluorescent protein has high chemical stability and light stability. Based on the related properties of the fluorescent protein, the fluorescent protein can be used in the fields of protein labeling, various types of fluorescence imaging and super-resolution photoelectric correlated imaging, and is used for tracking the structural and morphological changes of samples such as proteins, subcellular organelles, local cell regions and cells; the kit can be used for packaging related viruses or transgenic animals, marking specific proteins, specific organelles or specific cells, and realizing rapid transparent tissue imaging and expansion super-resolution imaging.

The present invention provides a method for detecting benign and malignant breast tumors and its application. Taking body fluid exosomes as samples, the present invention uses liquid chromatography tandem mass spectrometry to obtain the protein phenotypes of patients with benign and malignant breast tumors, establish a detection and / or prediction model for benign and malignant breast tumors based on proteomics, and provides a kit or chip for detecting benign and malignant tumors, as well as the application of protein markers for benign and malignant breast tumors in the preparation of the kit and / or chip. Compared with traditional detection methods such as tissue biopsy, the present invention has the characteristics of non-invasive and convenient detection, and can accurately distinguish whether the sample to be detected is a sample of benign or malignant breast tumor.

The invention provides a method for screening toxic chemicals capable of inducing mucus to highly secrete by utilizing a three-dimensional cell model of a human cell line, and belongs to the technical field of biotoxicity evaluation. The method comprises the following steps: firstly, carrying out suspension culture on 16HBE cells to obtain a three-dimensional cell model, respectively adding a culture solution containing a series of samples to be tested with different concentrations, incubating for 48 hours, and detecting to obtain an exposure concentration for inhibiting the cell activity by 20%; and then exposing the three-dimensional cell model in a culture solution containing a test sample with the concentration for 36-50 hours, detecting the expression condition of the mucus marker protein MUC5AC through an immunofluorescence chemical method, analyzing whether an experimental group and a negative control group have statistical difference or not, and if the experimental group and the negative control group have statistical difference, determining that the chemical has mucus high secretion toxicity. The method is easy and convenient to operate, low in cost and high in three-dimensional model construction efficiency, in-situ detection of the cell activity and the protein markers can be directly carried out in the culture pore plate, multiple biological index testing is facilitated, and a more comprehensive and systematic testing system can be expanded.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

A protein marker Nell-1 is provided that is present in a blood sample of a human in an amount associated with neurodegenerative diseases such as Alzheimer's disease (AD), mild cognitive impairment (MCI), and Parkinson's disease (PD). Also provided are corresponding diagnostic and therapeutic methods for these neurodegenerative diseases, as well as kits for diagnosing or treating neurodegenerative diseases.

The invention discloses a urine protein marker for diagnosing helicobacter pylori as well as application, a kit and a risk assessment model of the urine protein marker, and belongs to the technical field of biomedicine. And the protein marker is a combination of PHB1, C20orf202, CP and P0DOX5. Compared with a healthy control, the expression level of PHB1 in a helicobacter pylori patient is lowered, and the expression levels of C20orf202, CP and P0DOX5 in the helicobacter pylori patient are all increased. By detecting expression levels of PHB1, C20orf202, CP and P0DOX5, diagnosis of helicobacter pylori patients can be realized, detection capability and efficiency can be improved, intervention measures can be taken actively, and risks of diseases such as chronic gastritis, peptic ulcer, MALT lymphoma and gastric cancer can be reduced.